Calendario

Agosto. 2017
LunMarMierJueVierSabDom
 << < > >>
   1234
567891011
12131415161718
19202122232425
262728293031 

Anuncio

¿Quién está en línea?

Miembro: 0
Visitante: 1

rss Sindicación

En302014

09:28:19

Omeros Announces Positive Results From Phase 2a Trial Of Oms824 In Patients With Schizophrenia

 Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophreniaOmeros announces positive results from Phase 2a trial of OMS824 in patients with schizophreniaPublished on January 29, 2014 at 8:04 AM · No CommentsOmeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia . OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.In this Phase 2a randomized, double-blind, placebo-controlled trial, OMS824 was administered at two dose levels for two weeks to psychiatrically stable patients whose antipsychotic medications were temporarily discontinued or who continued their usual antipsychotic regimen. The trial enrolled 33 patients, and the results showed that OMS824 was well tolerated, with mild or moderate adverse events that were self-limited and resolved during the treatment period. The tolerability and pharmacokinetics of OMS824 were not affected by concomitant antipsychotic medications, allowing the drug to be developed as both a monotherapy and as adjunctive therapy in combination with currently approved antipsychotics. The plasma concentrations of OMS824 in the high-dose cohort were similar to levels that corresponded to greater than 60 percent target occupancy of PDE10 in a Phase 1 positron emission tomography (PET) trial. Given the small sample size, efficacy conclusions cannot be drawn but the data support continued development in schizophrenia and other neuropsychiatric conditions.The positive results from this Phase 2a trial suggest that dose adjustment will not be necessary when OMS824 is administered in combination with standard antipsychotic medications. Future Phase 2 and Phase 3 clinical trials in Omeros' schizophrenia program may evaluate OMS824 both as a single agent and as adjunctive treatment for cognitive impairment, acute exacerbation of symptoms, and/or inadequate response to antipsychotic medications.

We Think That Is Because Neural Replay Has Been Triggered While You Sleep.



visit this website http://www.news-medical.net/news/20140129/Omeros-announces-positive-results-from-Phase-2a-trial-of-OMS824-in-patients-with-schizophrenia.aspx



Natus Medical reports revenue of $90.6 million in fourth quarter 2013



 The Company's cash and cash equivalents increased $12 million to $56.1 million during the quarter while total debt was reduced by $10 million. "I am very pleased to report our fourth quarter results. We exceeded our revenue and earnings guidance and achieved record profitability. Our non-GAAP operating profit margin of 19.1% was extremely satisfying. As a result, we have established a new long term annual non-GAAP operating profit margin goal of 20%," said Jim Hawkins, President and Chief Executive Officer of the Company. "Our international revenues were higher than expected during the quarter with solid growth in the Pacific Rim and improving sales in Europe, while our domestic business remained stable." continued Mr. Hawkins. "The record 2013 results were highlighted by non-GAAP earnings growth of 61% to $1.03. Other major achievements include significantly improving operating margins, the successful integration of the Nicolet and Grass acquisitions and the reorganization of the Company into two business units - Neurology and Newborn Care," Hawkins added.

this content http://www.news-medical.net/news/20140129/Natus-Medical-reports-revenue-of-24906-million-in-fourth-quarter-2013.aspx



REM sleep, memory and depression: an interview with Dr Penny Lewis, University of Manchester



 For example, if you learned two lists of words, say words that were read aloud, and then you heard one list read aloud to you again while you were asleep, you would have a better memory of the list that was read to you in you sleep if you were tested on both lists the next day. We think that is because neural replay has been triggered while you sleep. This is actually a very old idea. However, the current work on this involves several really high profile scientific papers showing that this is really true, and the work that has done also allows us to understand why. We know that it?s about triggering this neural activity and strengthening up representations while you sleep. It is has been proposed that people who are depressed may be having too much REM. Please could you explain the reasoning behind this theory? Well, it?s not a theory - it?s an empirical observation that many people who are depressed have excessive amounts of REM, we know that.

visit our website http://www.news-medical.net/news/20140129/REM-sleep-memory-and-depression-an-interview-with-Dr-Penny-Lewis-University-of-Manchester.aspx


Admin · 34 vistas · Escribir un comentario

Vínculo permanente hacia el artículo completo

http://orlandobeross.hazblog.com/Blog-b1/Omeros-Announces-Positive-Results-From-Phase-2a-Trial-Of-Oms824-In-Patients-With-Schizophrenia-b1-p6.htm

Comentarios

Este artículo no tiene Comentario por el momento .....


Escribir un comentario

Estatuto de los nuevos comentarios: Publicado





Se mostrará tu URL


Por favor introduce el código contenido en las imágenes.


Texto del comentario

Opciones
   (Salvar el nombre, el mail y la URL en los cookies)